Research And Development
Health
Manufacturing

ACADIA Pharmaceuticals

$25.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.62 (2.45%) Today
+$0.03 (0.12%) After Hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, ETFs, and crypto commission-free!

About

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. Read More The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Employees
430
Headquarters
San Diego, California
Founded
1993
Market Cap
3.65B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.26M
High Today
$26.10
Low Today
$25.45
Open Price
$25.45
Volume
370.08K
52 Week High
$28.67
52 Week Low
$12.77

Collections

Research And Development
Health
Manufacturing
Pharmaceutical
Technology
Medical
Biotechnology

News

Yahoo FinanceMay 9

Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT

Q1 2019 ACADIA Pharmaceuticals Inc Earnings Call SAN DIEGO May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of ACADIA Pharmaceuticals Inc earnings conference call or presentation Wednesday, May 1, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Elena H. Ridloff ACADIA Pharmaceuticals Inc. - Executive VP & CFO...

47
The Motley FoolMay 8

Why Acadia Pharmaceuticals Stock Slumped in April

What happened Acadia Pharmaceuticals (NASDAQ:ACAD), a mid-cap biopharma, saw its shares decline by 10.8% last month, according to data from S&P Global Market Intelligence. What provoked this double-digit sell-off? Acadia's shares fell victim to the politically charged drug-pricing debate in the United States. While biopharma stocks in general struggled in April because of this hot-button issue, Acadia's shares were hit particularly hard because the company has aggressively raised the price of its Parkinso...

77
Yahoo FinanceMay 7

ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m. Pacific Time in Las Vegas. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com,...

30

Earnings

-$0.62
-$0.56
-$0.50
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.